AC Immune Targeting $50m IPO

Alzheimer's disease drug and vaccine developer AC Immune SA is aiming to raise $50m via an initial public offering that will take the company public on Nasdaq in the US. This follows a successful series E financing round in May this year that saw the company net $43.5m.

The Swiss company plans to use proceeds from the IPO to continue development of its lead product, the anti-Abeta antibody crenezumab, which is being researched as a passive immunization treatment for Alzheimer's disease. Crenezumab, which is currently in Phase III clinical trials, is partnered with Roche company, Genentech Inc.

A US Securities and Exchange Commission filing from AC Immune did not disclose how many shares it plans to sell...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip